BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3226722)

  • 1. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma.
    Ali IU; Campbell G; Lidereau R; Callahan R
    Oncogene Res; 1988 Sep; 3(2):139-46. PubMed ID: 3226722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-erbB-2 amplification in node-negative human breast cancer.
    Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
    Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
    Berger MS; Locher GW; Saurer S; Gullick WJ; Waterfield MD; Groner B; Hynes NE
    Cancer Res; 1988 Mar; 48(5):1238-43. PubMed ID: 2893663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
    Zhou D; Battifora H; Yokota J; Yamamoto T; Cline MJ
    Cancer Res; 1987 Nov; 47(22):6123-5. PubMed ID: 3664511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
    Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
    Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary studies on c-erbB-2 protooncogene in breast cancer].
    He LW
    Zhonghua Zhong Liu Za Zhi; 1992 May; 14(3):171-4. PubMed ID: 1356719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
    Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
    Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
    Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P
    Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.
    Zhou DJ; Ahuja H; Cline MJ
    Oncogene; 1989 Jan; 4(1):105-8. PubMed ID: 2915899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
    Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
    Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
    Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative detection of amplification of proto-oncogenes in breast cancer.
    Chen Y; Dong J; Lu Y; McGee JO
    Chin Med J (Engl); 1995 Nov; 108(11):849-54. PubMed ID: 8585979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The search for amplification of the ERBB-2 oncogene in human tumors].
    Imianitov EN; Chernitsa OI; Nikiforova IF; Titov KV; Khanson KP; Kniazev PG
    Vopr Onkol; 1992; 38(6):652-9. PubMed ID: 1300765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
    Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
    Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene.
    Singleton TP; Strickler JG
    Pathol Annu; 1992; 27 Pt 1():165-90. PubMed ID: 1346551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.